molecules of the month


selective CSF1R kinase inhibitor

oral, 30 mg BIW, phase III, cancer

from structure-based design

Molecular Cancer Therapeutics

Deciphera Pharmaceuticals

Chemical structure of molecule Vimseltinib (DCC-3014)
1 min read

The Deciphera CSF1R kinase inhibitor, vimseltinib (DCC-3014), is a selective oral TKI that induces an inactive conformation of CSF1R by biomimetically nucleating an array of 17 H-bonds in the switch control region of this switch control kinase. Several small and large molecule agents targeting CSF1R have been in development, and a small molecule CSF1R inhibitor (pexidartinib) was approved in 2019. Vimseltinib significantly inhibited CSF1R signaling in PK/PD models at doses as low as 3 mg/kg orally and depletes macrophages in efficacy models. Single agent and combination efficacy with anti-PD1 immunotherapy in a syngeneic mouse colorectal cancer model with effects on the adaptive immune system were also observed, in agreement with the hypothesis that certain macrophages play a role in tumor immune evasion. In…

request a trial

Drug Hunter is commited to helping industry innovators make informed decisions. Premium members have access to our library of the latest stories in science, written by scientists.

Request a trial to access insights powering the pros in our industry.

already a member? log in: